Medical/Pharmaceuticals

NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product

WUXI, China, Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORRO...

2026-08-19 17:00 1822

Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The performance reflected continued strong commercial momentum, dr...

2026-08-19 14:48 1444

Everest Medicines Announces Interim Results for First Half of 2026

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first hal...

2026-08-19 11:39 3398

GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma

* Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 * Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where additional effective treatment options are needed [...

2026-08-19 10:00 2539

Ping An Good Doctor Announces 2026 Interim Results

Corporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim ...

2026-08-19 09:09 2942

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-08-19 09:00 2195

CARsgen Therapeutics Announces 2026 Interim Results

SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights * Cash and cash equivalents were around RMB1,400 million as of June ...

2026-08-19 08:15 4179

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

* Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics develo...

2026-08-19 03:44 2082

/C O R R E C T I O N -- Rayence/

In the news release, Rayence Breaks the Boundaries of Point-of-Care Imaging with the Launch of Integrated Portable X-ray Diagnostic Solutions 'Anywhere-M' and 'Anywhere-V', issued 18-Aug-2026 by Rayence over PR Newswire, we are advised by the company that the first paragraph has been updated and ...

2026-08-19 01:22 2908

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27....

2026-08-18 22:15 2858

Frost & Sullivan: Juno Health Receives the 2026 North American Modular EHR Delivery Customer Value Leadership Recognition for Excellence in Cloud-Native EHR Innovation

The company stands out for delivering a scalable, cloud-native platform that enhances customer experience through flexible system ownership, operational efficiency, and cost-effective EHR modernization. SAN ANTONIO, Aug. 18, 2026 /PRNewswire/ -- This week we would like to congratulateJuno Health...

2026-08-18 21:00 1632

Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...

2026-08-18 17:02 2393

WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence

SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody i...

2026-08-18 12:03 3364

Enginprime Medical Closes $12M Series A Financing

Round exclusively led by Qiming Venture Partners; proceeds to fund China registration trial and overseas early-stage clinical development SHANGHAI and HANGZHOU, China, Aug. 17, 2026 /PRNewswire/ -- Enginprime Medical ("Enginprime" or the "Company"), a developer of percutaneous ventricular assist...

2026-08-18 08:00 3235

Connext Completes Enrollment in Phase 2 Trial of CNT201 in Dupuytren's Contracture

- All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive data could support expansion of CNT201 into Peyronie's disease and cellulite SEOUL, South Korea, Aug. 17, 2026 /PRNewswire/ -- Connext, a specialty...

2026-08-17 21:00 3207

U.S. Recruitment for Ohio State University Study Evaluating EmeTerm in Adults With Chronic Nausea and Vomiting

VANCOUVER, BC, Aug. 17, 2026 /PRNewswire/ -- Participant recruitment information for a clinical study being conducted at The Ohio State University has been publicly posted on ClinicalTrials.gov. The study, titled "Evaluating the Effect of Wearing a TENS Device in Nausea Relief," is also known as ...

2026-08-17 21:00 4457

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital Internatio...

2026-08-17 20:30 4737

OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors

— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a late c...

2026-08-17 20:00 4502

Kelun-Biotech Announces 2026 Interim Results

CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period"). Key information is as follows: * Re...

2026-08-17 19:18 6445

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

* Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages * Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is ...

2026-08-17 12:34 2913
1 ... 33343536373839 ... 642